Apatinib as first treatment for older adults with advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a pill called apatinib as a first treatment for older adults with advanced stomach or gastroesophageal junction cancer. It might help if you cannot or do not want to have chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years or older.
- You have been diagnosed with advanced stomach or gastroesophageal junction cancer.
- You have not had prior treatment for this cancer.
- You are unable or unwilling to receive chemotherapy.
- You have at least one measurable tumor and are generally in fair health.
- You can take oral medication and have a life expectancy of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a pill called apatinib in people whose cancer has spread to the belly and causes fluid to build up (malignant ascites). Apatinib works by cutting off the blood supply that tumors need to grow, which may help reduce the fluid and ease symptoms.
This trial studies whether combining camrelizumab (an immunotherapy) and apatinib (a targeted pill) can control advanced, unresectable stomach or gastroesophageal junction cancer that has grown after first treatment. It also looks at how safe the combination is.
This trial tests whether adding an immunotherapy drug (adebrelimab) and a targeted therapy (apatinib) to standard chemotherapy helps shrink stomach cancer before surgery. It aims to improve outcomes for people with advanced stomach cancer that cannot be removed or has spread.
This trial tests a combination of three drugs (adebrelimab, apatinib, and paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has progressed after immunotherapy. The goal is to see if this combination helps control the cancer longer.
This trial tests whether adding SHR-1701 (an immunotherapy) with or without apatinib (a targeted therapy) to standard chemotherapy before surgery can help treat gastric cancer. It is for people with stomach or gastroesophageal junction cancer that has spread to nearby lymph nodes but is still removable.
This trial tests a combination of two oral drugs, TAS-102 and apatinib, as a third-line treatment for advanced stomach cancer. It aims to see if this combination can help control the cancer when other treatments have not worked.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.